AVITA Medical Launches $3.0 Million Share Purchase Plan

After the market close on Friday, AVITA Medical Ltd (ASX: AVH) confirmed the opening of Share Purchase Plan to raise $3.0 million initially.

The company stated that the Share Purchase Plan on 4 December is now open from the next working day, i.e., 17 December 2018. Through this Share Purchase Plan, AVITA Medicals has offered the eligible shareholders to purchase up to a minimum of $1,000 at a purchase price of $0.08 per share. But each shareholder has the right to subscribe for a maximum of $15000 worth AVITA Medical shares.

Medical technology company, AVITA Medical targets to raise total $3.0 million from this SPP, however the company at its Board discretion may decide to raise additional funds for a maximum aggregate amount of $5.0 million. The company plans to use these funds for marketing and sales efforts to add a financial arm to the launch of RECELL® System in the U.S. market. Whereas, meeting the company’s working capital requirement and enhancing clinical research and development are the others key areas where the company proposes to use its fundraisings.

Moreover, the raising through Share Purchase Plan comes after $40.0million institutional placement offer. In the market release dated 4 December 2018, the company announced that it had received commitments for $40.0 million from international institutional investors across the US and Australia. The placement will be in two tranches, first, the settlement of $24.5 million without the need for prior shareholders’ approval and the second, including the acquisition of shareholders’ approval to settle remaining $15.2 million. For obtaining shareholders’ approval, the company has scheduled Extraordinary General Meeting to be held in January 2019.

Chief Executive Officer of AVITA Dr. Michael Perry stated, “Proceeds from this placement will underscore the company’s ability in releasing the opportunity provided by the FDA approval to the RECELL System.”

RECELL System provides an innovative method in the treatment of burns. It uses patients’ skin to produce Spray-On Skin™ Cells which in turn reduces the amount of donors’ skin requirement. AVITA told that RECELL System is designed in such a manner that it can be used independently at the point of care or could be combined with autografts depending on the depth of the burn injury.

Currently, the company is in progress of mailing SPP Booklet to its eligible shareholders. The Booklet read that Share Purchase Plan will close on 7 January 2019 and the new shares under SPP will be issued subsequently on 10 January 2019.

In the last trade, AVITA Medical’ stock concluded its day flat on the Australian Securities Exchange. However, 475,961 shares of AVITA changed hands as at 14 December 2018.

Further, in the last 5-day trade, AVH shares have witnessed a movement of 1.25% to close at $0.079. And the stock has climbed 26.98% over the past one year.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK